{
    "clinical_study": {
        "@rank": "60488", 
        "arm_group": [
            {
                "arm_group_label": "Aim1-Low salt diet", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will be provided with a diet from the Vanderbilt Clinical Research Center that will be controlled for salt content."
            }, 
            {
                "arm_group_label": "Aim 1-high salt diet", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will be provided with a diet from the Vanderbilt Clinical Research Center that will be controlled for salt content."
            }, 
            {
                "arm_group_label": "Aim2- low salt diet and epleronone-amlodipine", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects on a low salt diet will receive epleronone 50mg for 8 days and assessments will be made, then cross over to a low salt diet with amlodipine 5mg for 8days and assessments will be made."
            }, 
            {
                "arm_group_label": "aim2- lowsaltdiet and amlodipine-epleronone", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects on a low salt diet will receive amlodipine 5mg for 8 days and assessments will be made, then cross over to a low salt diet with epleronone 50mg for 8days and assessments will be made."
            }
        ], 
        "brief_summary": {
            "textblock": "Aim 1.Test the hypothesis that activation of the endogenous renin-angiotensin-aldosterone\n      system impairs glycemic control via effects on insulin sensitivity and insulin secretion.\n\n      Aim 2. Test the hypothesis that activation of the endogenous renin-angiotensin-aldosterone\n      system impairs insulin secretion and insulin sensitivity via an mineralocorticoid-receptor\n      dependent mechanism."
        }, 
        "brief_title": "Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism", 
        "condition": "Metabolic Syndrome", 
        "condition_browse": {
            "mesh_term": "Metabolic Syndrome X"
        }, 
        "detailed_description": {
            "textblock": "In aim 1 subjects are randomized to cross over between an 8 day high salt and 8 day low salt\n      diet and assessments are made.\n\n      In aim 2, subjects are randomized to a 2x2 cross over study with an 8 day low salt diet and\n      either eplerenone 50mg or amlodipine 5mg."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Ambulatory subjects, 18 to 70 years of age, inclusive\n\n          2. For female subjects, the following conditions must be met:\n\n               1. postmenopausal status for at least 1 year, or\n\n               2. status-post surgical sterilization, or\n\n               3. if of childbearing potential, utilization of adequate birth control and\n                  willingness to undergo urine beta-hcg testing prior to drug treatment and on\n                  every study day.\n\n          3. Metabolic Syndrome as defined by the presence of > 3 of the following:\n\n               1. Systolic Blood Pressure > 130 mm Hg OR Diastolic Blood Pressure > 85 mm Hg.\n\n               2. Glucose Intolerance (Fasting Plasma Glucose \u2265 100 mg/dL)\n\n               3. Increased triglyceride level > 150mg/dL (1.7mmol/L)\n\n               4. Decreased levels of HDL cholesterol (For males, less than 40 mg/dL; For females,\n                  less than 50 mg/dL)\n\n               5. Waist circumference (For males, greater than 40 inches; For females, greater\n                  than 35 inches)\n\n        Exclusion Criteria:\n\n          1. type 1 Diabetes\n\n          2. Type II Diabetes\n\n          3. Impaired renal function\n\n          4. Prior allergies to medications used in the study protocol\n\n          5. Screening plasma potassium >5.5 mmol/L or sodium <135 mmol/L\n\n          6. Cardiovascular disease\n\n          7. Use of hormone replacement therapy\n\n          8. Breast-feeding\n\n          9. Treatment with anticoagulants\n\n         10. History of serious neurologic disease\n\n         11. History or presence of immunological or hematological disorders\n\n         12. Diagnosis of asthma requiring use of inhaled beta agonist\n\n         13. Clinically significant gastrointestinal impairment\n\n         14. Impaired hepatic function\n\n         15. Hematocrit <35%\n\n         16. Any underlying or acute disease requiring regular medication which could possibly\n             pose a threat to the subject or make implementation of the protocol or interpretation\n             of the study results difficult, such as arthritis treated with non-steroidal\n             antiinflammatory drugs\n\n         17. Treatment with chronic systemic glucocorticoid therapy\n\n         18. Treatment with lithium salts\n\n         19. History of alcohol or drug abuse\n\n         20. Treatment with any investigational drug in the 1 month preceding\n\n         21. Mental conditions rendering the subject unable to understand the nature, scope and\n             possible consequences of the study\n\n         22. Inability to comply with the protocol, e.g., uncooperative attitude, inability to\n             return for follow-up visits, and unlikelihood of completing the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "57", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02034435", 
            "org_study_id": "131139"
        }, 
        "intervention": {
            "arm_group_label": [
                "Aim1-Low salt diet", 
                "Aim 1-high salt diet", 
                "Aim2- low salt diet and epleronone-amlodipine", 
                "aim2- lowsaltdiet and amlodipine-epleronone"
            ], 
            "intervention_name": "glucose and insulin testing", 
            "intervention_type": "Other"
        }, 
        "intervention_browse": {
            "mesh_term": "Amlodipine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 10, 2014", 
        "location": {
            "contact": {
                "email": "loretta.byrne@vanderbilt.edu", 
                "last_name": "Loretta Byrne, RN", 
                "phone": "615-322-2105"
            }, 
            "contact_backup": {
                "email": "holly.waldrop@vanderbilt.edu", 
                "last_name": "Holly Waldrop"
            }, 
            "facility": {
                "address": {
                    "city": "Nashville", 
                    "country": "United States", 
                    "state": "Tennessee", 
                    "zip": "37232-6602"
                }, 
                "name": "Vanderbilt University Medical Center"
            }, 
            "investigator": {
                "last_name": "James M Luther, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism", 
        "overall_contact": {
            "email": "loretta.byrne@vanderbilt.edu", 
            "last_name": "Loretta Byrne, RN", 
            "phone": "615-322-2105"
        }, 
        "overall_official": {
            "affiliation": "Vanderbilt University", 
            "last_name": "James M Luther, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Insulin secretion", 
            "safety_issue": "No", 
            "time_frame": "After 8 days of diet"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02034435"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Vanderbilt University", 
            "investigator_full_name": "James Matt Luther", 
            "investigator_title": "M.D., MSCI", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Insulin sensitivity", 
            "safety_issue": "No", 
            "time_frame": "after 8 days of diet"
        }, 
        "source": "Vanderbilt University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Vanderbilt University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}